Navigation Links
New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
Date:5/20/2008

subjects with disease duration less than three years, and 68 percent versus 34 percent for subjects with disease duration of at least three years; clinical remission: 28 percent versus 8 percent and 35 percent versus 12 percent, respectively; mucosal healing: 56 percent versus 29 percent and 63 percent versus 35 percent, respectively.

At week 30, clinical response, clinical remission and mucosal healing rates for the combined REMICADE treatment group (5 mg/kg and 10 mg/kg) were also significantly higher than the placebo group (P < 0.01) regardless of disease duration; clinical response: 49 percent versus 19 percent for subjects with disease duration less than three years, and 54 percent versus 34 percent for subjects with disease duration of at least three years; clinical remission: 28 percent versus 10 percent, and 35 percent versus 15 percent, respectively; mucosal healing: 47 percent versus 20 percent ,and 52 percent versus 32 percent, respectively. A Cochran-Mantel-Haenszel test stratified by baseline corticosteroid refractory status was used to compare REMICADE with placebo within each disease duration subgroup.

Ulcerative colitis is a chronic inflammatory disease of the colon and large intestine that affects approximately half a million Americans and can lead to frequent hospitalizations, surgery and loss of work productivity. Both UC and Crohn's disease are known collectively as inflammatory bowel diseases, or IBD. Approved in 1998 by the U.S. Food and Drug Administration as the first anti-tumor necrosis factor (TNF)-alpha therapy, REMICADE received its initial approval for the treatment of Crohn's disease and has since become the first and only anti-TNF-alpha therapy approved for the treatment of UC and pediatric Crohn's disease. A Phase 3 study evaluating the efficacy and safety of REMICADE for the treatment of pediatric UC is currently ongoing.

Impact of Anti-TNF Therapies on Absence from Work Among Employees with IBD

Also pres
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  As the pharmaceutical industry works to ... Compliance professionals are placing a significant emphasis on ... today by LRN, the leader in Ethics & ... of respondents expressed that clarity on company values ... E&C training programs (57%), trumping understanding of the ...
(Date:3/5/2015)... 2015 Bayer HealthCare announced today that it ... Foundation of the American Society of Clinical Oncology (ASCO) ... platform designed to unlock vast quantities of information about ... "Bayer is proud to join ASCO and the ... Data to help people whose lives have been affected ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... 24, 2011 Genelux Corporation, a privately held, clinical ... cancer and inflammatory diseases, today announced the appointment of ... Board of Directors. Dr. Fenton,s appointment expands the Genelux ... someone who helped to build one of the world,s ...
... VIEW, Calif., Jan. 24, 2011 Based on its ... market, Frost & Sullivan recognizes BeClose with the 2010 ... of the Year for its innovative BeClose System and ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) While PERS have ...
Cached Medicine Technology:Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4
(Date:3/5/2015)... (PRWEB) March 05, 2015 Central Nebraska ... their practice including the brand’s new logo and optimized ... showcase the practice’s modern approach to expert diagnostic imaging, ... mobile-optimized and be built to be a resource for ... community. With automated forms, communication and referral functionality, video ...
(Date:3/5/2015)... 05, 2015 On March 2, 2015, ... Labiaplasty on the Rise, Plastic Surgeons Say,” that comments ... Society for Aesthetic Plastic Surgery and the ... reported a year-over-year doubling of surgical butt augmentations performed ... in the article, this increase can be attributed to ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 Dr. ... Surgeon ( http://www.orthopedicsurgeonnyc.com ) has been named by ... New York Metro area. Dr. Glashow has been selected ... authoritative guide to the top specialty care doctors in ... The prestigious Castle Connolly program, which carefully screens and ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... 2009, Octapharma AG realized a ... euro as of year-to-date June 2008, an increase of 27%. ... of sales increased proportionally more than the turnover, decreasing gross ... costs. , Due to increased efficacy in other areas, Octapharma ...
... patients , FRIDAY, Oct. 2 (HealthDay News) -- Treatment ... surgery in ulcerative colitis patients by almost half, a ... of the colon and often leads to surgical removal ... patients who received either an inactive placebo or infliximab ...
... not cell type, may lead to better treatments, researchers ... new way to classify stomach cancers could lead to ... with the disease, researchers say. , For a study ... the researchers analyzed 301 stomach tumors from people in ...
... , HOUSTON, Oct. 2 Cyberonics, Inc. (Nasdaq: ... of EEG-based seizure detection to build on its position ... On October 1, 2009, Cyberonics entered into a License ... a range of technology and patents in exchange for ...
... Ill Anterior cruciate ligament (ACL) injuries are one of ... thousands of patients undergo reconstructive surgery to repair these injuries. ... 2009 issue of The Journal of Bone and Joint ... is increasing substantially and women and younger patients are more ...
... ... the Ziostation® 3D advanced visualization software to the French market as an integrated product. ... Montreuil, France ... advanced visualization and analysis software for medical imaging and Global Imaging Online, French ...
Cached Medicine News:Health News:Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market 2Health News:New Classification Proposed for Stomach Cancers 2Health News:Cyberonics Announces Epilepsy Technology Collaborations 2Health News:Cyberonics Announces Epilepsy Technology Collaborations 3Health News:Cyberonics Announces Epilepsy Technology Collaborations 4Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:Ziosoft and Global Imaging Online Announce Reseller Agreement for France and Maghreb Area 2
... assayed quality control material used for ... electrolyte, metabolite, and CO-Oximeter instrumentation. The ... it the ideal choice for Bayer ... in three (3) levels for monitoring ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
Medicine Products: